Teva Pharmaceutical Industries Limited (NYSE:TEVA) engages in the development and distribution of generic and other medicines, and biopharmaceutical products. The one-month return of Teva ...

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Ustekinumab products may decrease the protective ... Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel ...

Teva's Senior Vice President emphasized ... including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows ... safety and efficacy as the innovator brand product, at offering cost-effective alternative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.